HomeCompareAKYA vs KMB

AKYA vs KMB: Dividend Comparison 2026

AKYA yields 155.04% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AKYA wins by $29.54M in total portfolio value
10 years
AKYA
AKYA
● Live price
155.04%
Share price
$1.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.59M
Annual income
$13,040,704.30
Full AKYA calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — AKYA vs KMB

📍 AKYA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAKYAKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AKYA + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AKYA pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AKYA
Annual income on $10K today (after 15% tax)
$13,178.29/yr
After 10yr DRIP, annual income (after tax)
$11,084,598.66/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, AKYA beats the other by $11,080,169.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AKYA + KMB for your $10,000?

AKYA: 50%KMB: 50%
100% KMB50/50100% AKYA
Portfolio after 10yr
$14.82M
Annual income
$6,522,957.81/yr
Blended yield
44.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

AKYA
Analyst Ratings
2
Buy
7
Hold
Consensus: Hold
Price Target
$4.98
+286.0% upside vs current
Range: $2.40 — $7.50
Altman Z
-4.2
Piotroski
4/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AKYA buys
0
KMB buys
0
No recent congressional trades found for AKYA or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAKYAKMB
Forward yield155.04%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$29.59M$45.9K
Annual income after 10y$13,040,704.30$5,211.33
Total dividends collected$27.44M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold
Analyst price target$4.98$123.00

Year-by-year: AKYA vs KMB ($10,000, DRIP)

YearAKYA PortfolioAKYA Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$26,204$15,503.88$11,314$613.68+$14.9KAKYA
2$66,007$37,968.38$12,865$759.19+$53.1KAKYA
3$160,011$89,383.96$14,709$943.96+$145.3KAKYA
4$373,718$202,506.35$16,919$1,180.17+$356.8KAKYA
5$841,906$442,027.47$19,588$1,484.33+$822.3KAKYA
6$1,831,486$930,646.81$22,838$1,879.06+$1.81MAKYA
7$3,851,778$1,892,087.52$26,832$2,395.60+$3.82MAKYA
8$7,840,307$3,718,904.61$31,788$3,077.63+$7.81MAKYA
9$15,463,748$7,074,619.86$38,000$3,986.82+$15.43MAKYA
10$29,586,915$13,040,704.30$45,872$5,211.33+$29.54MAKYA

AKYA vs KMB: Complete Analysis 2026

AKYAStock

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Full AKYA Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this AKYA vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AKYA vs SCHDAKYA vs JEPIAKYA vs OAKYA vs KOAKYA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.